Literature DB >> 11045702

Two-phase helical CT for detection of early gastric carcinoma: importance of the mucosal phase for analysis of the abnormal mucosal layer.

J H Lee1, Y K Jeong, D H Kim, B K Go, Y J Woo, S Y Ham, S O Yang.   

Abstract

PURPOSE: To evaluate the efficacy of two-phase dynamic helical computed tomography (CT), including the gastric mucosal phase, for detection of early gastric carcinoma with typical hyperattenuating and atypical nonhyperattenuating enhancement patterns.
METHOD: Two-phase helical CT scanning was performed using the water-filling method as negative oral contrast material for 212 patients with proven adenocarcinoma on endoscopic biopsy. Two gastrointestinal radiologists prospectively analyzed the focal alterations of the inner hyperattenuating mucosal layer and the outer hypoattenuating layer before the information obtained at barium study and pathologic examination was available. The first, so-called mucosal phase was obtained at 38-45 seconds after the start of intravenous injection of contrast material for a total of 150 ml/sec at a rate of 4 ml/sec to obtain maximum enhancement of the inner mucosal layer. The second delayed phase was obtained at 3 minutes.
RESULTS: Fifty-four cases of early gastric cancer were suspected on two-phase helical CT preoperatively. Postoperatively, 49 cases of early gastric cancer were pathologically confirmed. The detection rate for the typical hyperattenuating early gastric cancer, that is the type I enhancement pattern defined as the localized thickening of the inner hyperattenuating layer, using two-phase helical CT was 18% (9/49 patients). The type 2 enhancement pattern, defined as the focal interruption of the inner hyperattenuating mucosal layer without abnormal enhancement of the outer hypoattenuating layer on the mucosal phase, was seen in 15 cases. These were pathologically confirmed as early gastric cancer IIb + IIc (three patients), IIc (four patients), IIc + IIa (one patient), IIc + III (three patients), IIb + IIc (one patient), and advanced cancer (T2) lesions (three patients). The type 3 enhancement pattern was defined as the focal polypoid protrusion of the inner hyperattenuating layer without abnormal enhancement of the outer thickened hypoattenuating layer on the mucosal phase, and was seen in seven patients who were pathologically confirmed with early gastric cancer IIb + IIc (three patients), IIc + IIa (one patient), and IIc + lIb (three patients). The lesions became less distinct on the delayed phase. Five T2 advanced gastric cancers were falsely interpreted as early gastric cancer. The detection rate for early gastric cancer after considering type 2 and 3 atypical enhancement patterns was increased to 57% (28/49 patients).
CONCLUSION: Helical CT with two-phase scan including the mucosal phase was efficient for identifying the enhancement patterns of early gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045702     DOI: 10.1097/00004728-200009000-00020

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  11 in total

1.  Evaluation of contrast-enhanced helical hydro-CT in staging gastric cancer.

Authors:  Wen-Zhou Wei; Jie-Ping Yu; Jun Li; Chang-Sheng Liu; Xiao-Hua Zheng
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 2.  Trends in oncological CT imaging: clinical application of multidetector-row CT and 3D-CT imaging.

Authors:  Takuya Ueda; Kensaku Mori; Manabu Minami; Ken Motoori; Hisao Ito
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

3.  Detection of early gastric cancer using hydro-stomach CT: blinded vs unblinded analysis.

Authors:  Ki Jeong Park; Min Woo Lee; Ji Hyun Koo; Yulri Park; Heejung Kim; Dongil Choi; Soon Jin Lee
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

4.  Comparison between blinded and partially blinded detection of gastric cancer with multidetector CT using surgery and endoscopic submucosal dissection as reference standards.

Authors:  H J Kim; D H Lee; Y T Ko
Journal:  Br J Radiol       Date:  2010-06-15       Impact factor: 3.039

5.  Prediction of intraoperative bleeding during endoscopic treatment in patients with early gastric cancers: utility of contrast-enhanced MDCT gastrography and the wall-carving image technique.

Authors:  Daisuke Tsurumaru; Satoshi Kawanami; Masahiro Komori; Kiyohisa Hiraka; Yoshiki Asayama; Hiroshi Honda
Journal:  Jpn J Radiol       Date:  2012-12-18       Impact factor: 2.374

6.  Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings.

Authors:  M Moschetta; A A Stabile Ianora; A Anglani; A Marzullo; A Scardapane; G Angelelli
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

7.  Decreased stage migration rate of early gastric cancer with a new reconstruction algorithm using dual-energy CT images: a preliminary study.

Authors:  Cen Shi; Huan Zhang; Jing Yan; Baisong Wang; Lianjun Du; Zilai Pan; Fuhua Yan
Journal:  Eur Radiol       Date:  2016-06-08       Impact factor: 5.315

8.  Dual Energy Spectral CT Imaging in the assessment of Gastric Cancer and cell proliferation: A Preliminary Study.

Authors:  Sai-Ming Cheng; Wei Ling; Jiong Zhu; Jian-Rong Xu; Lian-Ming Wu; Hong-Xia Gong
Journal:  Sci Rep       Date:  2018-12-04       Impact factor: 4.379

9.  Gastric cancer staging with dual energy spectral CT imaging.

Authors:  Zilai Pan; Lifang Pang; Bei Ding; Chao Yan; Huan Zhang; Lianjun Du; Baisong Wang; Qi Song; Kemin Chen; Fuhua Yan
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

10.  Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study.

Authors:  Yuntai Cao; Guojin Zhang; Jing Zhang; Yingjie Yang; Jialiang Ren; Xiaohong Yan; Zhan Wang; Zhiyong Zhao; Xiaoyu Huang; Haihua Bao; Junlin Zhou
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.